Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLU2 | ISIN: SE0009414576 | Ticker-Symbol: OND
Stuttgart
05.09.25 | 21:34
0,414 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOPEPTIDES AB Chart 1 Jahr
5-Tage-Chart
ONCOPEPTIDES AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,4130,46019:03

Aktuelle News zur ONCOPEPTIDES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.08.Oncopeptides AB: Oncopeptides publishes disclosure document regarding rights issue199THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND...
► Artikel lesen
27.08.Oncopeptides - Targeted oncology with commercial momentum290Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for difficult-to-treat cancers, with a focus on haematological diseases. Its lead product, Pepaxti, was approved...
► Artikel lesen
26.08.XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025188Das Instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025 The instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY is traded ex capital adjustment...
► Artikel lesen
ONCOPEPTIDES Aktie jetzt für 0€ handeln
25.08.Oncopeptides AB: Oncopeptides enters into additional guarantee commitments, rights issue fully guaranteed109THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND...
► Artikel lesen
21.08.Oncopeptides Q2 2025 slides: 135% sales growth overshadowed by rights issue announcement3
21.08.Oncopeptides AB: Oncopeptides publishes Q2 report 2025103Stockholm - August 21, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2025. "This...
► Artikel lesen
30.07.Oncopeptides AB: Oncopeptides Partners with SD Pharma to further broaden Pepaxti reach in Spain234Stockholm, July 30, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces a partnership with SD Pharma, a leading Spanish pharmaceutical...
► Artikel lesen
09.07.Oncopeptides AB: Oncopeptides announces net sales for Q2 2025249Stockholm, July 9, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the net sales for the second quarter of 2025. Oncopeptides...
► Artikel lesen
22.05.Oncopeptides AB: Bulletin from the Annual General Meeting in Oncopeptides AB (publ)184Stockholm, Sweden - The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 22 May 2025. At the Annual General Meeting, the following principal resolutions were passed. The...
► Artikel lesen
20.05.Oncopeptides AB: Oncopeptides launches new real-world evidence study of Pepaxti in Spain, first patient enrolled297Stockholm, May 20, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the first patient has been enrolled in its new...
► Artikel lesen
15.05.Oncopeptides Q1 2025 slides: 160% sales growth as European expansion accelerates4
15.05.Oncopeptides AB: Oncopeptides publishes Q1 report 2025224Stockholm - May 15, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2025. "The first...
► Artikel lesen
16.04.Oncopeptides AB: New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients243Stockholm, April 16, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further...
► Artikel lesen
27.02.Oncopeptides AB: Oncopeptides publishes year-end report 2024415Stockholm - February 27, 2025 - Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2024. "Pepaxti sales increased about 35 percent...
► Artikel lesen
07.11.24Oncopeptides AB: Oncopeptides publishes Q3 report 2024283Stockholm - November 7, 2024 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2024. "In the...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,9